Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.
Sign Up to like & getrecommendations! Published in 2022 at "Rheumatology"
DOI: 10.1093/rheumatology/keac015
Abstract: OBJECTIVES The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial compared hematopoietic stem cell transplant (HSCT) to cyclophosphamide (CYC) treatment in patients with early systemic sclerosis (SSc) with progressive skin and lung or kidney involvement. Here we… read more here.
Keywords: subset abnormalities; phenotype; lymphocyte subset; therapy ... See more keywords